Study on Selinexor as Maintenance Therapy for Advanced or Recurrent Endometrial Cancer with P53 Wild-Type

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of endometrial cancer, including specific types like endometrioid, serous, undifferentiated, and carcinosarcoma.
• Have P53 wild-type status confirmed by specific genetic testing.
• Completed at least 12 weeks of platinum-based chemotherapy and achieved a partial or complete response.
• Have not received adjuvant or neoadjuvant therapy for Stage I-III disease.
• Have a good performance status, meaning they are fully active or have some restrictions but can still perform light work.
• Have adequate bone marrow and organ function based on recent lab tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 90 days after the last dose.
• Must be able to start the study drug 3 to 8 weeks after finishing chemotherapy.
• Must sign an informed consent form agreeing to participate in the study.

Exclusion Criteria

• Have certain types of uterine cancer, like clear cell or small cell carcinoma with neuroendocrine differentiation.
• Have received a blood or platelet transfusion within 2 weeks before starting the study.
• Are on high-dose steroid therapy.
• Have not recovered from major surgery within 28 days before starting the study.
• Have significant side effects from previous cancer treatments that have not improved.
• Have had recent palliative radiotherapy for pain control.
• Have gastrointestinal issues that could affect the absorption of the study drug.
• Cannot tolerate anti-nausea medications.
• Have an active infection requiring treatment within 1 week of screening.
• Have a serious psychiatric or medical condition that could interfere with the study.
• Have previously been treated with an XPO1 inhibitor.
• Have stable disease or progression on the post-chemotherapy scan.
• Have received any other cancer treatment within 3 weeks before starting the study.
• Have had major injuries or surgery within 14 days before starting the study.
• Have another cancer that has not been disease-free for at least 3 years, except for certain non-threatening cancers.
• Have a history of allergic reactions to similar drugs.
• Have active brain metastases that are not adequately treated.
• Are pregnant or breastfeeding.
• Have any other serious illness or condition that could affect participation in the study.